Navigation Links
Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
Date:5/17/2010

5 million in the prior year period and primarily reflected the Company's more effective cost control efforts. Year-over-year spending reduction stemmed primarily from lower advertising, marketing and promotion, as well as salaries, wages and related benefits.

Research and development expenses totaled $1.1 million, consistent with those in the prior year period. The Company is obligated to make monthly payment to the designated university/institute to support two cooperative research and development agreements which were signed in fiscal 2008.

Income from operations rose 3.1% to $13.7 million from $13.3 million, primarily reflecting lower year-over-year operating expenses.

Other income was $5.0 million, as compared to other expenses of $1.1 million for the three months ended March 31, 2009. The increase was mainly due to an $11.6 million non-cash gain related to the change in the fair value of derivative liabilities, partly offset by $6.6 million interest expenses and non-cash amortization expense related to debt discount and debt issuance costs related to the convertible debentures, as compared to $1.2 million in the third quarter of 2009.

GAAP net income for the three months ended March 31, 2010 was $15.2 million, as compared to $8.9 million in the year ago quarter. Basic earnings per share (EPS) were $1.33, compared with $0.86 a year ago. Diluted EPS assumes the conversion of the Company's convertibl
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
2. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
3. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
4. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
5. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
7. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
8. DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors
9. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
10. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010 First Quarter Earnings Conference Call on Monday, May 17, 2010 at 9:30 a.m. ET
11. Jazz Pharmaceuticals Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ... agreement with Hitachi Koki of Japan ... North America . NuAire will utilize its network ... and Canada to offer assistance in application ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014   Evidera ... healthcare industry, announced that the Center for Drug Evaluation ... released its first draft qualification guidance document for a ... of Exacerbations of Chronic Pulmonary Disease Tool [EXACT] for ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
(Date:7/10/2014)... to 70% of Parkinson,s disease (PD) patients experience ... life. Some patients have disturbed sleep/wake patterns such ... other patients may be subject to sudden and ... patients may exhibit REM-sleep behavior disorder (RBD), characterized ... before motor symptoms appear. A review in the ...
(Date:7/10/2014)... Rutgers University-Newark says the human brain operates much the ... that could provide a better understanding of schizophrenia, bipolar ... an estimated 13.6 million Americans. , In newly published ... an assistant professor at the Center for Molecular and ... a person at rest is basically the same as ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:Working to loosen the grip of severe mental illness 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... the 150 million customer mark, an intense debate continues ... once led by nonprofits. "Microfinance Meets the Market," just ... advances the debate, presenting new research from Jonathan Morduch ... University,s Wagner Graduate School of Public Service, and Robert ...
... better balance in a slippery situation , , FRIDAY, Feb. ... where the footing is unstable helped train them to ... says a University of Illinois at Chicago study. ... develops fall prevention strategies that can be used in ...
... Ill., Feb. 20 Abbott ( NYSE: ABT ) ... from the European Commission for its acquisition of Advanced ... the outstanding shares of common stock of AMO. ... the condition to the tender offer related to European ...
... CHADDS FORD, Pa. and DANBURY, Conn., Feb. 20 ... Pharmaceuticals (Nasdaq: PPCO ) announced today that ... LLC regarding the production and sale of generic formulations ... Endo and Penwest have agreed to dismiss their ...
... FOR RELEASE UNTIL 4:00 P.M., ET, FRIDAY, FEBRUARY 20, ... Bride, (651) 695-2795, jmacbride@aan.com , Young Smokers Increase ... start smoking before age 17 may increase their risk ... released today that will be presented at the American ...
... Treatment targeting damaged brain areas did not bring significant ... (HealthDay News) -- An experimental laser treatment of ... stroke patients, researchers report. , The trial was the ... stroke. , In the trial, the researchers at the ...
Cached Medicine News:Health News:Research reveals best paths for success as microfinance sector grows 2Health News:Adapting Gait May Help Elderly Avoid Falls 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 2Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 4Health News:Laser Therapy Disappoints in Stroke Trial 2
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Inquire...
Guaranteed leak-proof , Teflon coating is impervious to corrosive materials , Shock-resistant , NBS tolerances of accuracy , Thermometers are 225 mm long with an immersion length of 35 mm ...
... efficient refrigerator on the market today. The ... unit. The contoured drain channels away moisture ... walls are coated with a tough, baked-on ... door is reversible. The interior of the ...
Medicine Products: